EWA
INMB icon

EverSource Wealth Advisors’s INmune Bio INMB Stock Holding History

EverSource Wealth Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06K Buy
938
+857
+1,058% +$1.22K ﹤0.01% 3841
2025
Q4 		$126 Buy
+81
New +$145 ﹤0.01% 4079
2025
Q2 		– Sell
-9
Closed -$70 – 4304
2025
Q1 		$70 Buy
+9
New +$71 ﹤0.01% 3869

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EverSource Wealth Advisors's INMB Position: Q1 2026 in Review

EverSource Wealth Advisors increased its INmune Bio (INMB) stake by 1,058% in Q1 2026, buying an estimated $1.22K and bringing the position to 938 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

EverSource Wealth Advisors first reported a position in INMB in Q1 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • EverSource Wealth Advisors held 938 shares of INmune Bio worth $1.06K as of Q1 2026.
  • EverSource Wealth Advisors bought 857 INmune Bio shares in Q1 2026, an estimated $1.22K.
  • INmune Bio made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3841 holding.
  • EverSource Wealth Advisors first reported a position in INmune Bio in Q1 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.